0001341004-20-000241.txt : 20200609 0001341004-20-000241.hdr.sgml : 20200609 20200608175243 ACCESSION NUMBER: 0001341004-20-000241 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200609 DATE AS OF CHANGE: 20200608 EFFECTIVENESS DATE: 20200609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Correvio Pharma Corp. CENTRAL INDEX KEY: 0001036141 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-29338 FILM NUMBER: 20950246 BUSINESS ADDRESS: STREET 1: 6TH FLOOR STREET 2: 1441 CREEKSIDE DRIVE CITY: VANCOUVER STATE: A1 ZIP: V6J 4S7 BUSINESS PHONE: 1-604-677-6905 MAIL ADDRESS: STREET 1: 6TH FLOOR STREET 2: 1441 CREEKSIDE DRIVE CITY: VANCOUVER STATE: A1 ZIP: V6J 4S7 FORMER COMPANY: FORMER CONFORMED NAME: Cardiome Pharma Corp DATE OF NAME CHANGE: 20040625 FORMER COMPANY: FORMER CONFORMED NAME: CARDIOME PHARMA CORP DATE OF NAME CHANGE: 20000407 15-12G 1 form15.htm 15-12G


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 000-29338
Correvio Pharma Corp.
(Exact name of registrant as specified in its charter)

1441 Creekside Drive, 6th floor
Vancouver, British Columbia, Canada
V6J 4S7, Canada
(604) 677-6905
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, without par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
☒
Rule 12g-4(a)(2)
☐
Rule 15d-6
☐
Rule 12h-3(b)(1)(i)
☒
Rule 12h-3(b)(1)(ii)  
☐
Rule 15d-22(b)
☐


Approximate number of holders of record as of the certification or notice date: One (1)*

*Effective May 27, 2020, the Registrant and ADVANZ PHARMA Corp. Limited (“ADVANZ”) completed a court-approved statutory plan of arrangement under the Canada Business Corporations Act pursuant to which ADVANZ, through its wholly-owned subsidiary, acquired all of the issued and outstanding shares of the Registrant.


Pursuant to the requirements of the Securities Exchange Act of 1934, Correvio Pharma Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 
     
 
Correvio Pharma Corp.
         
         
Date: June 8, 2020
  
By:
 
/s/ Adeel Ahmad
     
 
Name: Adeel Ahmad
     
 
Title: CFO/Director